渤健Biogen (BIIB) 2012年年度报告「NASDAQ」.pdf

1、A Company Aligned.A Mission Defined.Mother,Dog Lover,InspirationLISA SINDONI2012 ANNUAL REPORTBIOGENIDEC.COM/AR201243080.indd A43080.indd A4/17/13 12:06 PM4/17/13 12:06 PM08 09 10 11 12$4,089$4,377$4,716$5,049$5,516Revenues$in millions08 09 10 11 12$3.66$4.12$5.15$5.90$6.53*Non-GAAP Diluted EPS*$08

2、09 10 11 12$1,286$909$1,452$1,520$1,625Free Cash Flow*$in millions*2012 Non-GAAP diluted EPS was impacted by a tax correction which increased tax expense by$29 million and reduced EPS by approximately 12 cents*Non-GAAP diluted EPS and free cash fl ow are non-GAAP fi nancial measures.A reconciliation

3、 of GAAP to non-GAAP diluted EPS and free cash fl ow amounts are set forth on pages 14 and 15 of this annual report.43080.indd B43080.indd B4/17/13 12:06 PM4/17/13 12:06 PM 1For everyone who counts on Biogen Idec,2012 was an extraordinary year a period of significant transformation and remarkable ac

4、complishments across the organization.Since our last annual report,Biogen Idec has matured as a vibrant organization.Our core business has grown,we are preparing for several potential product launches in the near future,and we have made real progress in enhancing our early stage research and develop

5、ment(R&D)pipeline.Dear Fellow Shareholders:GEORGE A.SCANGOS,PH.D.Chief Executive Offi cer43080.indd 143080.indd 14/17/13 12:06 PM4/17/13 12:06 PM the beginning of 2012,we reported results from fi ve pivotal clinical trials four of which met their endpoints,and all of which were scientifi cally valua

6、ble.We substantially improved our R&D platform while developing a new approach to the way in which innovation is generated and nurtured in the biopharmaceutical sector.We have strengthened our production capabilities and continued our internal cultural transformation.Today we are fully aligned behin